Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1681

4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL

9:00AM-11:00AM: Abstract Number: 1652

A HPLC-SRM-MS Based Method for the Detection of Adherence to Low-Dose Oral Methotrexate

9:00AM-11:00AM: Abstract Number: 1647

A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1642

A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1654

A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1631

Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 1641

B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens

9:00AM-11:00AM: Abstract Number: 1636

Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year

9:00AM-11:00AM: Abstract Number: 1639

Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years

9:00AM-11:00AM: Abstract Number: 1667

Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1651

Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database

9:00AM-11:00AM: Abstract Number: 1635

Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1671

Discovery of PRN1008, a Novel, Reversible Covalent BTK Inhibitor in Clinical Development for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1677

Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1632

Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?

9:00AM-11:00AM: Abstract Number: 1678

Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?

9:00AM-11:00AM: Abstract Number: 1638

Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate

9:00AM-11:00AM: Abstract Number: 1640

Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1655

Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan

9:00AM-11:00AM: Abstract Number: 1675

Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks

9:00AM-11:00AM: Abstract Number: 1683

Epithelial Changes in Response to Tocilizumab Combined with Methotrexate in Rheumatoid Arthritis: Evaluated on Circulating Fragments of Type IV Collagen

9:00AM-11:00AM: Abstract Number: 1657

Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1663

Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor

9:00AM-11:00AM: Abstract Number: 1659

Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA

9:00AM-11:00AM: Abstract Number: 1633

Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months

9:00AM-11:00AM: Abstract Number: 1649

Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 1666

Mitochondrial Haplogroups in Patients with Rheumatoid Arthritis with Respect to Biological Treatment

9:00AM-11:00AM: Abstract Number: 1643

Modified-Release Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-Release Tofacitinib and Impact of Food

9:00AM-11:00AM: Abstract Number: 1629

Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis

9:00AM-11:00AM: Abstract Number: 1672

One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1668

Patterns of Relapse in the Rheumatoid Arthritis Cohort Treated with Rituximab at University College London

9:00AM-11:00AM: Abstract Number: 1674

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1630

Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents

9:00AM-11:00AM: Abstract Number: 1670

Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1656

Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment

9:00AM-11:00AM: Abstract Number: 1658

Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA

9:00AM-11:00AM: Abstract Number: 1644

Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 1680

Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1669

Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1682

Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor

9:00AM-11:00AM: Abstract Number: 1664

Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.

9:00AM-11:00AM: Abstract Number: 1676

Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update

9:00AM-11:00AM: Abstract Number: 1648

The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1634

The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1673

The Transcription Factor Nuclear Protein Transcriptional Regulator 1 May Contribute to Increased Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1637

TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1650

Tocilizumab Monotherapy in Early Rheumatoid Arthritis: Data from Two Phase 3 Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1645

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

9:00AM-11:00AM: Abstract Number: 1661

Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine

9:00AM-11:00AM: Abstract Number: 1662

Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission

9:00AM-11:00AM: Abstract Number: 1665

Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1653

Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1660

Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy

9:00AM-11:00AM: Abstract Number: 1679

Vicm Is a Novel Biomarker of Macrophage Activity Evaluated in a Phase IIb Clinical Trial of Mavrilimumab

9:00AM-11:00AM: Abstract Number: 1646

Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].